Results 131 to 140 of about 1,923,383 (256)

Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor.

, 2014
Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen ...
P Darcy (18763603), D Gilham (18763600), Tess Chee (13027890), Liza Raymond (13082100)   +3 more
core  

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

Chimeric antigen receptor cell therapies: From anticancer immunity to tissue repair and neural regeneration

Originally developed as breakthroughs in cancer immunotherapy, Chimeric antigen receptor cell therapies have recently attracted attention because of their potential to promote tissue repair and functional restoration.
Aarchi A. Bharadia, Vibha G. Kanjani, Kashvy R. Morakhia   +2 more
core   +1 more source

FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape

Advanced Science, EarlyView.
FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu, Xingwei Xie, Xiaohuan Wu, Suidong Ouyang, Yang Zhou, Kang Wen, Yutong Zhong, Yuyang Chen, Handuo Wang, Yuan Gao, Ling Jiang, Hui Li, Wenli Zhao, Abai Xu, Enguang Bi   +14 more
wiley   +1 more source

Chimeric antigen receptor-based therapies beyond cancer [PDF]

Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology.
Velasco de Andrés, María, Lozano, Francisco, Català, Cristina, Gutiérrez Hernández, María del Mar, Isamat, Marcos, Carrillo-Serradell, Laura, Muñoz Sánchez, Guillermo   +6 more
core   +1 more source

Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's Disease

Advanced Science, EarlyView.
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung, Xu Wang, Bin Liu, Raktim Roy, Nancy Jaiswal, Ratan K. Rai, Yuichiro Takagi, Cen Gao, Lifan Zeng, Ho‐Yin Lo, Reagan K. Wohlford, Ryan K. Higgins, Bruce T. Lamb, Anantha Shekhar, Anita C. Bellail, Chunhai Hao   +15 more
wiley   +1 more source

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment

Frontiers in Immunology, 2017
Primary human natural killer (NK) cells recognize and subsequently eliminate virus infected cells, tumor cells, or other aberrant cells. However, cancer cells are able to develop tumor immune escape mechanisms to undermine this immune control.
Olaf Oberschmidt, Stephan Kloess, Ulrike Koehl   +2 more
doaj   +1 more source

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells

Cancer Cell, 2019
SUMMARY The high expression across multiple tumor types and restricted expression in normal tissues make B7-H3 an attractive target for immunotherapy. We generated chimeric antigen receptor (CAR) T cells targeting B7-H3 (B7-H3.CAR-Ts) and found that B7 ...
Hongwei Du, K. Hirabayashi, Sarah Ahn, N. Kren, S. Montgomery, Xin-Hui Wang, Karthik Tiruthani, B. Mirlekar, Daniel Michaud, K. Greene, S. Herrera, Yang Xu, Chuang Sun, Yu-Hui Chen, Xingcong Ma, Cristina R. Ferrone, Y. Pylayeva-Gupta, J. Yeh, Rihe Liu, B. Savoldo, S. Ferrone, G. Dotti   +21 more
semanticscholar   +1 more source

Multifunctional Zinc Glycyrrhizinate‐Integrated Gel for Enhanced Probiotic Delivery and Alleviation of Acute and Spontaneous Colitis

Advanced Science, EarlyView.
Multifunctional oral delivery system—L. reuteri@ZGM—act as both a carrier and therapeutic adjuvant, providing ROS scavenging, and mucin‐interactive properties tailored to the IBD microenvironment. This bioactive gel safeguards L. reuteri from gastric degradation, enhances mucosal adhesion, and promotes long‐term retention at inflamed sites, thereby ...
Mengyun Peng, Xiaochun Chen, Wei Li, Shu Tang, Jun Zhou, Xia Wu, Dan Yuan, Zhongyan Shan, Junfeng Shi   +8 more
wiley   +1 more source

An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer

American journal of hematology/oncology, 2019
Chimeric antigen receptor (CAR) T‐cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen.
Steven Feins, Weimin Kong, E. Williams, M. Milone, J. Fraietta   +4 more
semanticscholar   +1 more source